Umeå universitets logga

umu.sePublikationer
Ändra sökning
ExporteraLänk till posten
Permanent länk

Direktlänk
BETA

Projekt

Projekttyp/Bidragsform
Projektbidrag
Titel [sv]
UTVÄRDERING AV NYA CANCERSPECIFIKA LÄKEMEDEL
Titel [en]
EVALUATION OF NOVEL CANCER SPECIFIC DRUGS
Abstract [en]
We have in our previous research supported by VR 2012-2015 identified a novel and unique cancer drug target which regulates invasion and metastasis of prostate cancer cells. We have in collaboration with SciLifeLab Drug Development Platform (DDP) during the last year generated more than 10 recombinant murine and human antibodies directed against our novel cancer drug target. By using established cell based assays and xenograft models for prostate cancer in my research group, we will investigate the potential usefulness of the recombinant antibodies to prevent invasion and metastasis of aggressive prostate cancer. We have in previous animal studies found that monoclonal antibodies against our drug target,  prevented invasion and metastasis of aggressive prostate cancer cells. The project will be carried out in collaboration with SciLifeLab (DDP) during the next year. Our cancer drug target is patented as we have a unique and novel approach to prevent cancer metastasis (described in detail in the research program). The long term goal is to investigate the clinical usefulness of this novel specific cancer drug to prevent metastatic spreading of aggressive prostate cancer cells (alone or in combination with other cancer drugs). The number of patients dying due to metastatic prostate cancer will increase nationally, in the close future due to the expected increase of prostate cancer in Sweden (a result of an elderly population), as well as globally, due to changes in life style.
ProjektledareLandström, Marene
Koordinerande organisation
Umeå universitet
Forskningsfinansiär
Tidsperiod
2016-01-01 - 2016-12-31
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
DiVA, id: project:1407Projekt id: 2016-06125_VR

Sök vidare i DiVA

Cancer och onkologi

Sök vidare utanför DiVA

GoogleGoogle Scholar